Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept.
Priori
R
R
Alessandri
C
C
Magrini
L
L
Cassarà
E A M
EA
Ceccarelli
F
F
Modesti
M
M
Croia
C
C
Bombardieri
M
M
Valesini
G
G
D000068879:Adalimumab; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000378:metabolism*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D009707:Nucleosomes / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D009707:Nucleosomes; D018124:Receptors, Tumor Necrosis Factor; D002097:C-Reactive Protein; D000068879:Adalimumab; D000068800:Etanercept